WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement

Core Viewpoint - bioAffinity Technologies, Inc. has entered into a securities purchase agreement for a registered direct offering and a concurrent private placement to raise capital for its noninvasive cancer detection tests [1][2]. Group 1: Offering Details - The company will sell 2,048,294 shares of common stock at a price of $1.30 per share [1]. - In addition, the company will issue common warrants to purchase up to 2,662,782 shares at an exercise price of $1.50 per share [1]. - The gross proceeds from the offering are expected to be approximately $2,662,782, excluding any proceeds from the exercise of the warrants [2]. Group 2: Closing and Regulatory Information - The closing of the offering is anticipated to occur on or about October 21, 2024, subject to customary closing conditions [2]. - The shares will be issued under an effective shelf registration statement previously filed with the SEC [3]. - The private placement of the warrants will rely on an exemption from registration under Section 4(a)(2) of the Securities Act [4]. Group 3: Company Background - WallachBeth Capital LLC is acting as the sole placement agent for the offering, providing capital markets and investment banking services to the healthcare sector [5].